Irodanoprost is under clinical development by Mesentech and currently in Phase I for Duchenne Muscular Dystrophy.

(MENAFN- EIN Presswire) Duchenne ... clinical decision-making, including genetic counseling, prenatal diagnosis, and consideration of mutation-specific therapies. The Duchenne Muscular Dystrophy ...

This year’s top stories on Duchenne muscular dystrophy (DMD ... A histone deacetylase inhibitor, givinostat has shown in clinical trials to improve functional outcomes like stair-climbing ...

Patients with Duchenne muscular dystrophy now have new hope with gene ... Mason received the multi-million dollar dose as part of a clinical trial. Now it’s Dawson’s turn.

An estimated 1 in 8,000 individuals, or 870,000 people worldwide, are affected by Facioscapulohumeral muscular dystrophy ...

application to initiate the CONNECT2-EDO51 clinical trial in patients with Duchenne muscular dystrophy (DMD). The FDA indicated they will provide an official clinical hold letter to the Company ...

Wedbush initiated coverage on Solid Biosciences, Inc. SLDB, a gene therapy company focused on treating Duchenne muscular dystrophy (DMD ... projects toward clinical trials in 2025.

PepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51 Phase 2 Study of PGN-EDO51 for Duchenne Muscular Dystrophy -Company continues to advance PGN-EDO51 in ...

"The submission of the BLA marks a pivotal step for Capricor and those impacted by DMD. This BLA is the culmination of a body of work that has been focused on bringing this potentially ...

UC Davis Health has premiered a new documentary on a family’s urgent journey across the globe to get their toddler in a clinical trial for patients with Duchenne Muscular Dystrophy, or DMD.

application to initiate the CONNECT2-EDO51 clinical trial in patients with Duchenne muscular dystrophy (DMD). The FDA indicated they will provide an official clinical hold letter to the Company ...